Toshihiko Doi

National Cancer Center Hospital East

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

SciProfiles

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

National Cancer Center Hospital East

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Research Subjects

Research Interests

Toshihiko Doi has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

Kohei Shitara
National Cancer Center East, Kashiwa, Japan
74 shared publications
Yasutoshi Kuboki
Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan
54 shared publications
Takashi Kojima
47 shared publications
Hiroyoshi Nishikawa
Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan
45 shared publications
Akihito Kawazoe
Department of Gastroenterology and Gastrointestinal oncology National Cancer Center Hospital East Chiba Japan
43 shared publications
Shota Fukuoka
National Cancer Center 1 Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC) Tokyo, Japan
42 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Descriptive summary of serum PF-07062119 PK parameters (with 400 μg priming dose) for cycle 1.
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Descriptive summary of serum PF-07062119 PK parameters (with 400 μg priming dose) for cycle 1.
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of CD3+, CD8+, CD8+/GZMB+, PD-L1+. Immune cell fold changes in C3D1 biopsies from baseline (screening) biopsies
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of CD3+, CD8+, CD8+/GZMB+, PD-L1+. Immune cell fold changes in C3D1 biopsies from baseline (screening) biopsies
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
PET imaging visualization of CD8+ tracer retention in tumor lesions BOT
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S6 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
PET imaging visualization of CD8+ tracer retention in tumor lesions BOT
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 5 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Descriptive summary of serum PF-07062119 PK parameters (without priming dose) for cycle 1.
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 5 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Descriptive summary of serum PF-07062119 PK parameters (without priming dose) for cycle 1.
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of best overall response, objective response (confirmed), PFS, and DOR based on investigator assessment (RECIST v1.1) in all patients (full analysis set).
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 3 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of best overall response, objective response (confirmed), PFS, and DOR based on investigator assessment (RECIST v1.1) in all patients (full analysis set).
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of incidence of DLTs, TEAEs, and treatment-related TEAEs in patients who received at least one dose of PF-07062119 (safety analysis set).
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 2 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of incidence of DLTs, TEAEs, and treatment-related TEAEs in patients who received at least one dose of PF-07062119 (safety analysis set).
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Results from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Results of serum cytokine responses
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Results from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Results of serum cytokine responses
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Treatment-related TEAEs (in >15% patients) by preferred term and maximum CTCAE grade in patients who received at least one dose of PF-07062119
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S3 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Treatment-related TEAEs (in >15% patients) by preferred term and maximum CTCAE grade in patients who received at least one dose of PF-07062119
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Patient disposition flow diagram
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Patient disposition flow diagram
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Representativeness of study participants with advanced gastrointestinal cancers
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Representativeness of study participants with advanced gastrointestinal cancers

Show all